



Topical and Intralesional Immunotherapy for Skin Cancer

Guest Editor:

Dr. Ángeles Flórez

1. Department of Dermatology,
Pontevedra University Hospital,
Pontevedra, Spain
2. DIPO Research Group, Galicia
Sur Health Research Institute (IIS
Galicia Sur) SERGAS-UVIGO, Vigo,
Spain

Deadline for manuscript
submissions:

31 July 2024

Message from the Guest Editor

Skin cancer is the most common form of human cancer and has an increasing annual incidence. Currently, its management and follow-up represent a challenge for patients, physicians, and health systems due to its associated morbidity, impact on health-related quality of life, costs, and death.

Immunotherapy is revolutionizing cancer management, enabling much higher disease control rates. The immune system has been long recognized as a key element involved in the pathogenesis, progression, and persistence of skin cancer. From this scenario arises the clinical relevance of skin-directed immunotherapy, an expanding therapeutic pipeline that can be administered in different modalities and combinations without inducing systemic toxicity.

In this Special Issue of *Cancers*, experts in the field will update and critically analyse the available evidence on topical and intralesional immunotherapy for skin cancer, focusing on non-melanoma skin cancer, melanoma, and primary cutaneous lymphoma. New promising approaches will also be reviewed.





cancers



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (*Oncology*) / CiteScore - Q1 (*Oncology*)

Contact Us

Cancers Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
X@Cancers_MDPI